Rossing P - Search Results

1

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.

Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC; DAPA-CKD Investigators. Heerspink HJL, et al. Among authors: rossing p. Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282. doi: 10.1093/ndt/gfz290. Nephrol Dial Transplant. 2020. PMID: 32030417 Free PMC article. Clinical Trial.

2

The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.

Parving HH, Rossing P. Parving HH, et al. Among authors: rossing p. Curr Opin Nephrol Hypertens. 1994 May;3(3):292-300. doi: 10.1097/00041552-199405000-00010. Curr Opin Nephrol Hypertens. 1994. PMID: 7922255 Review.

3

Monitoring kidney function in diabetic nephropathy.

Rossing P, Astrup AS, Smidt UM, Parving HH. Rossing P, et al. Diabetologia. 1994 Jul;37(7):708-12. doi: 10.1007/BF00417696. Diabetologia. 1994. PMID: 7958543

4

Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy.

Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Ricard S, Poirer O, Parving HH. Tarnow L, et al. Among authors: rossing p. Nephrol Dial Transplant. 1996 Jun;11(6):1019-23. Nephrol Dial Transplant. 1996. PMID: 8671962

5

Optimal dose of losartan for renoprotection in diabetic nephropathy.

Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Andersen S, et al. Among authors: rossing p. Nephrol Dial Transplant. 2002 Aug;17(8):1413-8. doi: 10.1093/ndt/17.8.1413. Nephrol Dial Transplant. 2002. PMID: 12147788

6

Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.

Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving HH. Andersen S, et al. Among authors: rossing p. Nephrol Dial Transplant. 2003 Feb;18(2):293-7. doi: 10.1093/ndt/18.2.293. Nephrol Dial Transplant. 2003. PMID: 12543883

7

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L. Parving HH, et al. Among authors: rossing k, rossing p. Semin Nephrol. 2004 Mar;24(2):147-57. doi: 10.1016/j.semnephrol.2003.11.003. Semin Nephrol. 2004. PMID: 15017527 Review.

8

Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.

Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk C, Tarnow L, Parving HH. Persson F, et al. Among authors: rossing p. Diabetes. 2006 Dec;55(12):3550-5. doi: 10.2337/db06-0827. Diabetes. 2006. PMID: 17130503 Clinical Trial.

9

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.

Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving HH. Persson F, et al. Among authors: rossing p. Kidney Int. 2008 Jun;73(12):1419-25. doi: 10.1038/ki.2008.68. Epub 2008 Mar 12. Kidney Int. 2008. PMID: 18337712 Free article. Clinical Trial.

10

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.

Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk CG, Tarnow L, Parving HH. Persson F, et al. Among authors: rossing p. Scand J Clin Lab Invest. 2008;68(8):731-8. doi: 10.1080/00365510802187226. Scand J Clin Lab Invest. 2008. PMID: 18609080 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

742 results

Search Page